

ESCCA 2024
Preliminary programme *(subject to change)*

WEDNESDAY 25 SEPTEMBER 2024

PRE-CONFERENCE WORKSHOPS

09:00-12:30	WS01	Workshop 1: MRD in ALL	Eivissa 1
<p>Organisers: Ester Mejstrikova (Prague, CZ) and Michaela Reiterová (Prague, CZ) Level: Intermediate/Advanced. Max. 20 places, pre-registration required</p> <p>MRD in ALL is essential tool in monitoring treatment efficacy. Despite its frequent use in the majority of modern treatment protocols several issues remains unresolved and questionable. In BCP ALL regeneration of hematogones hampers sensitivity and interpretation might be subjective. Targeted treatment anti-19, anti-CD20 and anti-CD22 influences regeneration of normal B cell precursors. Newly defined subsets of BCP ALL namely characterised by DUX4 rearrangement frequently undergo lineage switch towards monocytic lineage and B cell oriented MRD fails in detection of switched blasts. In T ALL we will discuss the role of immunophenotypic heterogeneity in design of T ALL MRD panels. Category of immature T ALLs ("early T cell precursor leukemia") is frequently characterised by germline configuration of TCR genes resulting in unavailability of MRD assessment by molecular techniques and flow cytometry is crucial in this subset. During the workshop we will analyze FCS files of B and T ALL MRD samples.</p>			
09:00-09:45		MRD in BCP ALL introduction	Ester Mejstrikova
09:45-10:30		MRD in BCP ALL practical part	Ester Mejstrikova, Michaela Reiterova
10:30-11:00		<i>Coffee break</i>	
11:00-11:45		MRD in T ALL introduction	Michaela Reiterová
11:45-12:30		MRD in T ALL practical part	Michaela Reiterová, Ester Mejstrikova
<i>Lunch on your own</i>			
09:00-12:30	WS02	Workshop 2: Extracellular vesicles: welcome to the nano-flow world	Eivissa 2
<p>Organiser: Alfonso Blanco (Dublin, IE) Level: Intermediate/Advanced. Max. 20 places, pre-registration required</p> <p>During this workshop, we will explain the technological difficulties of working with extracellular vesicles (EVs), from sample collection, storage and preparation and how they can influence in the final results. We will also cover the technical considerations for the analysis of the EVs as well as what are the best practices to optimize samples and instruments for this analysis. A practical session will take place showing how to perform the instrument set up, data analysis and how to detect some issues such as swarming effect. The programme will follow soon.</p>			
<i>Lunch on your own</i>			
09:00-12:30	WS03	Workshop 3: A practical approach to Immunodeficiency Analysis	Eivissa 3
<p>Organiser: Fariba Tahami (London, UK) and Martín Pérez-Andrés (Salamanca, ES) Level: Intermediate. Max. 20 places, pre-registration required</p> <p>The participants will be trained in the following topics: i) screening of immunodeficiencies of the lymphoid system by flow cytometry including: severe and non-severe combined immunodeficiencies, predominantly antibody deficiencies, and disease of immune dysregulation, ii) flow cytometry predictors of complication and short-term survival in CVID, and iii) functional test for validation of monogenic immunodeficiencies.</p>			
09:00-9:30		Diagnostic screening and classification of PID using flow cytometry	Martin Perez-Andres
9:30-10:15		Screening of PID by FCM: Live case orientation	Martin Perez-Andres
10:15-10:45		Pathogenic classification of CVID patients using FCM	Martin Perez-Andres
10:45-11:00		<i>Coffee break</i>	
11:00-12:30		Functional tests for validation of monogenic immunodeficiencies	Fariba Tahami
<i>Lunch on your own</i>			

09:00-12:30	WS04	Workshop 4: Panel design and optimisation in standard and spectral flow-cytometry	Eivissa 4
Organiser: Cristina Teodosio (Salamanca, ES) and Julio Pozo (Salamanca, ES) Level: Intermediate. Max. 20 places, pre-registration required			
Flow cytometry has grown exponentially in the last decade, with the introduction of instruments able to evaluate more (>20) fluorescent parameters simultaneously, the development of spectral flow cytometry, and the increasing number of (new) fluorochromes. While these developments have allowed for new applications and more flexibility, the process of effective panel design has become increasingly more complex. During this workshop, we will discuss the technical advances and differences in conventional and spectral flow cytometry, and how to address the panel design for the different platforms. We will also cover strategies for assay optimisation and data troubleshooting and have a guided panel design practical session.			
09:00 - 09:45		Conventional vs. spectral flow cytometry: principles and technical advances	Cristina Teodosio
09:45 - 10:30		Principles and good practices for panel design in flow cytometry	Cristina Teodosio
10:30-11:00		<i>Coffee break</i>	
11:00 – 11:30		Assay optimisation and data troubleshooting	Julio Pozo
11:30 – 12:30		Practical panel design exercise for conventional and spectral instruments	Cristina Teodosio/Julio Pozo
<i>Lunch on your own</i>			

CONFERENCE PROGRAMME

14:30-15:30	PLE01	Opening & Keynote Lecture 1	Auditorium Mallorca
14:30-14:45		Welcome address by the ESCCA President & Announcements	Francesco Buccisano (Rome, IT)
14:45-15:30	PLE01-01	Keynote Lecture: Phenotype of Innate Myeloid Cells	Christina Teodosio (Salamanca, ES)
15:30-16:00	IPP01	ESCCA Industrial Partner Presentation - Sysmex	
16:00-16:30		<i>Coffee break</i>	Exhibition area
16:30-17:30	PLE02	ESCCA-ICCS joint session Challenging lineage definition in Acute Leukemia	Auditorium Mallorca
16:30-17:00	PLE02-01	Mixed phenotype/mixed lineage acute leukemia	Sindhu Cherian (Washington, USA)
17:00-17:30	PLE02-02	Undifferentiated Acute Leukemia	Daniel Boyer (Michigan, USA)
17:30-18:00		Clinical Cytometry Best Original Paper Award 2023-2024	Auditorium Mallorca
18:00-19:00		Welcome Reception	Palma Room

THURSDAY 26 SEPTEMBER 2024

09:30-10:45	PAR01	The role of immunophenotype in Myelodysplastic Syndromes	Auditorium Mallorca
09:30-10:00	PAR01-01	Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group	Wolfgang Kern (Munich, DE)
10:00-10:30	PAR01-02	Lecture title to be confirmed	Katharina Götze (Munich, DE)
10:30-10:45		Q&A	
09:30-10:45	PAR02	Cancer - Monitoring of cancer-specific immunity	Sala Menorca
09:30-10:00	PAR02-01	Extensive profiling of graft-versus-tumor and graft-versus-host T cell responses after allogeneic stem cell transplantation	Marieke Griffioen (Leiden, NL)
10:00-10:30	PAR02-02	Extensive phenotypic and functional evaluation of graft-versus-tumor T cell responses and exploration of dendritic cell vaccination to boost anti-tumor immunity	Willemijn Hobo (Nijmegen, NL)
10:30-10:45		Q&A	
10:45-11:15		<i>Coffee break, Exhibition, Posters</i>	Exhibition area
11:15-11:45	IPP02	ESCCA Industrial Partner Presentation 2 - Beckman Coulter	
11:45-12:45	PLE03	ESCCA/SIC Joint Session Role of FCM in evaluating novel immunotherapy strategies for hematological malignancies	Auditorium Mallorca
11.45-12.15	PLE03-01	Generation of allogeneic CD123 CAR-T cells for AML treatment	Ines Zugasti (Barcelona, ES)
12.15-12.45	PLE03-02	Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo	Luis Álvarez (Madrid, ES)
12:45-14:15		<i>Lunch break, Exhibition, Posters</i>	Exhibition area
12:45-14:15		Novartis Corporate Satellite Round Table Discussion on PNH (pre-registration required; max. 20 places)	
14:15-15:15	PLE04	Selected Best Abstracts 1	Auditorium Mallorca
14:15-14:30	PLE04-01	High prevalence of circulating T-cell clones of uncertain significance (T-CUS) among healthy individuals using highly sensitive flow-cytometry approaches	Julia Almeida (Salamanca, ES)
14:30-14:45	PLE04-02	The role of CAR-T cell-derived extracellular vesicles as new therapeutic tool in hematological malignancies	Pasquale Simeone (Chieti, IT)
14:45-15:00	PLE04-03	BCL2/TCL1 as a proposed new combination for the determination of MRD in patients with blastic plasmacytoid dendritic cell neoplasm	Angeliki Kotsiafti (Athens, GR)
15:00-15:15	PLE04-04	CD34+CD38- Leukemia Stem Cells are Associated with Prognosis in Non-Intensively Treated Acute Myeloid Leukemia	Tom Reuvekamp (Amsterdam, NL)
15:15-15:45	IPP03	ESCCA Industrial Partner Presentation 3 - Cytek Biosciences	Auditorium Mallorca
15:45-16:15		<i>Coffee break, Exhibition, Posters</i>	Exhibition area
16:15-17:30	PAR03	New FCM-based approach of T-cell chronic neoplasms	Auditorium Mallorca
16:15-16:45	PAR03-01	Combined TRBC1 and TRBC2 to assess T-cell clonality by cytometry	Min Shi (Rochester, USA)
16:45-17:15	PAR03-02	Classification of T-CLPD based on expert-independent FCM tools	Julia Almeida (Salamanca, ES)
17:15-17:30		Q&A	
16:00-17:30	PAR04	Reproductive Immunology	Sala Menorca
16:15-16:45	PAR04-01	Menstrual blood; from waste to non-invasive immunomonitoring of reproductive health	Renate van der Molen (Nijmegen, NL)
16:45-17:15	PAR04-02	Mass Cytometry and the Dynamic Changes at the Maternal-Fetal Interface Throughout Pregnancy	Michael Eikmans (Leiden, NL)
17:15-17:30		Q&A	
17:40-18:45		ESCCA General Assembly	Sala Menorca

FRIDAY 27 SEPTEMBER 2024

09:30-10:45	PAR05	MRD in the modern treatment of leukemia	Auditorium Mallorca
09:30-10:00	PAR05-01	Advancing innovation and standardization in FLOW-MRD detection for pediatric AML	Margarita Maurer-Granofzsky (Vienna, AT)
10:00-10:30	PAR05-02	Advanced MRD analysis with NGS/MFC	Christian Vonk (Rotterdam, NL)
10:30-10:45		Q&A	
09:30-10:45	PAR06	Basic and practical immunology	Sala Menorca
09:30-10:00	PAR06-01	The effect of CMV infection and HLA-type on peripheral blood lymphocyte reference values	Alejandra Pera (Córdoba, ES)
10:00-10:30	PAR06-02	Standardization of Workflow and Flow Cytometry Panels for Quantitative Expression Profiling of Surface Antigens on Blood Leukocyte Subsets: An HCDM CDMaps Initiative	Tomas Kalina (Prague, CZ)
10:30-10:45		Q&A	
10:45-11:15		<i>Coffee break, Exhibition, Posters</i>	Exhibition area
11:15-12:30	PLE05	Interactive case presentations in Hemato-Oncology	Auditorium Mallorca
11:15-12:30		Case series	Sindhu Cherian (Washington, USA) and Min Shi (Rochester, USA)
12:30-14:00		<i>Lunch break, Exhibition, Posters</i>	Exhibition area
14:00-14:30	PLE06	ESCCA/ESID joint session	Auditorium Mallorca
14:00-14:30	PLE06-01	FC applications in HLH	Yenan Bryceson (Stockholm, SE)
14:30-15:30	PLE07	Selected Best Abstracts 2	Auditorium Mallorca
14:15-14:30	PLE07-01	From data to diagnosis: biomarker discovery in amyotrophic lateral sclerosis	Davide Raineri (Vercelli, IT)
14:30-14:45	PLE07-02	Functional defects in patients with immune dysregulation due to CTLA-4 mutations	Rik Brooimans (Rotterdam, NL)
14:45-15:00	PLE07-03	The modulation of ICAM1 and ICAM3 in Th2 cell subsets of Severe eosinophilic asthmatic patients is mediated by IL-33	Laura Bergantini (Siena, IT)
15:00-15:15	PLE07-04	Artificial Intelligence to empower the potential of flow cytometry for the identification of nanoplastics in water and body fluid samples	Francesca D'Ascanio (Chieti, IT)
15:30-16:00		<i>Coffee break, Exhibition, Posters</i>	Exhibition area
16:00-17:15	PAR07	Artificial Intelligence and quality control in flow-cytometric data	Auditorium Mallorca
16:00-16:30	PAR07-01	Possibilities of AI for clinical cytometry data analysis	Yvan Saeys (Ghent, BE)
16:30-17:00	PAR07-02	Pre-processing, potential of automated methods for MRD detection	Sarah Bonte (Ghent, BE)
17:00-17:15		Q&A	
16:00-17:15	PAR08	Extracellular Vesicles	Sala Menorca
16:00-16:30	PAR08-01	Extracellular vesicles as potential biomarkers. Considerations for sample processing, analysis and sorting	Alfonso Blanco (Dublin, IE)
16:30-17:00	PAR08-02	Labeling extracellular vesicles for flow cytometry analyses	Paola Lanuti (Chieti, IT)
17:00-17:15		Q&A	
18:45-23:00		Conference Dinner at Son Termes <i>Pre-registration required; a fee applies</i>	

SATURDAY 28 SEPTEMBER 2024

09:30-10:45	PAR09	Focus on IVDR	Auditorium Mallorca
09:30-10:00	PAR09-01	LDT and IVDR: what's new?	Marie-Christine Béné (Nantes, FR)
10:00-10:30	PAR09-02	IVDR-compliant validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry	Orianne Wagner-Ballon (Créteil, FR)
10:30-10:45		Q&A	
09:30-10:45	PAR10	Clinical cytometry in transplantation	Sala Menorca
09:30-10:00	PAR10-01	NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma	Simon Mitchell (Brighton, UK)
10:00-10:30	PAR10-02	Integration of Polychromatic Immunophenotype in a Multi-Omic Study of Patients with Idic-15,a Rare Neurodevelopmental Disease	Enrique O'Connor
10:30-10:45		Q&A	
10:45-11:15		<i>Coffee break, Exhibition, Posters</i>	Exhibition area
11:15-11:45	PLE08	Keynote Lecture 2: CAR-NK cells	Auditorium Mallorca
11:15-11:45	PLE08-01	Off-the-shelf CD70-targeting CAR NK cells: Preclinical and early phase clinical updates	Sunil Acharya (Houston, USA)
11:45-13:00	PLE09	Immunology: Interactive case presentation	Auditorium Mallorca
11:45-13:00		Case series	Willemijn Hobo (Nijmegen, NL) and Renate van der Molen (Nijmegen, NL)
13:00-13:15	PLE10	ESCCA Awards session & Closure	Auditorium Mallorca
		Best Oral Presentation & Best Poster Awards ESCCA 2025 Closing Address	